RIBI ImmunoChem Research

Ribi ImmunoChem Research was a pioneering biotechnology company focused on the development of novel adjuvants and immunotherapeutics derived from bacterial cell wall components. The company is most famous for creating Monophosphoryl Lipid A (MPL), a highly effective and safe immune-stimulating agent that targets Toll-like receptor 4. Following its acquisition by Corixa and subsequently GSK, Ribi's MPL technology became a fundamental component of several major global vaccines, including those for HPV (Cervarix) and shingles (Shingrix). Based in Hamilton, Montana, the company's research significantly advanced the understanding of innate immunity and vaccine enhancement. Today, its former headquarters continues to serve as a vital manufacturing hub for the global vaccine supply chain.